retatrutide parkinson clinical trial VisualAbstract: reduces body weight by 17.5% in patients with obesity retatrutide clinical trial parkinson retatrutide

Is retatrutide safe

Additionally, further investigations are underway to explore potential additional uses of tirzepatide in the clinical management of other cardiometabolic conditions associated with obesity, including heart failure and non-alcoholic (or metabolic-dysfunction associated) steatohepatitis (NASH/MASH)

Watch: doctors explain why GLP-1 patches don't work Published research cited in this article This statement has not been evaluated by the Food and Drug Administration

Regular follow-up is essential for all patients on GLP-1 therapy

The 10-year cumulative incidence of MACE was 23.7% (95% CI 20.027.6%) in the metabolic surgery group and 34.0% (95% CI 28.144.2%) in the GLP-1 RA group (adjusted HR 0.65 (95% CI 0.510.82)

For ongoing support, TrimRX offers customized GLP-1 programs starting at $199 for Injectable Semaglutide